Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

The ABC subfamily A transporters: multifaceted players with incipient potentialities in cancer.

Pasello M, Giudice AM, Scotlandi K.

Semin Cancer Biol. 2019 Oct 9. pii: S1044-579X(19)30250-0. doi: 10.1016/j.semcancer.2019.10.004. [Epub ahead of print] Review.

PMID:
31605751
2.

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.

Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, Pasello M, Parra A, Carrabotta M, Ferracin M, Palladini A, Ianzano ML, Giusti V, Ruzzi F, Magnani M, Donati DM, Picci P, Lollini PL, Scotlandi K.

Sci Rep. 2019 Aug 21;9(1):12174. doi: 10.1038/s41598-019-48634-y.

3.

Construction of Human Naïve Antibody Gene Libraries.

Pasello M, Mallano A, Flego M, Zamboni S, Giudice AM, Scotlandi K.

Methods Mol Biol. 2018;1827:73-91. doi: 10.1007/978-1-4939-8648-4_4.

PMID:
30196492
4.

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K.

Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29.

5.

Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R.

Mancarella C, Pasello M, Manara MC, Toracchio L, Sciandra EF, Picci P, Scotlandi K.

Front Endocrinol (Lausanne). 2018 Apr 20;9:178. doi: 10.3389/fendo.2018.00178. eCollection 2018.

6.

Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy.

Mancarella C, Pasello M, Ventura S, Grilli A, Calzolari L, Toracchio L, Lollini PL, Donati DM, Picci P, Ferrari S, Scotlandi K.

Clin Cancer Res. 2018 Aug 1;24(15):3704-3716. doi: 10.1158/1078-0432.CCR-17-2602. Epub 2018 Apr 27.

7.

CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Manara MC, Pasello M, Scotlandi K.

Genes (Basel). 2018 Mar 13;9(3). pii: E159. doi: 10.3390/genes9030159. Review.

8.

CD99 at the crossroads of physiology and pathology.

Pasello M, Manara MC, Scotlandi K.

J Cell Commun Signal. 2018 Mar;12(1):55-68. doi: 10.1007/s12079-017-0445-z. Epub 2018 Jan 6. Review.

9.

CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.

Manara MC, Terracciano M, Mancarella C, Sciandra M, Guerzoni C, Pasello M, Grilli A, Zini N, Picci P, Colombo MP, Morrione A, Scotlandi K.

Oncotarget. 2016 Nov 29;7(48):79925-79942. doi: 10.18632/oncotarget.13160.

10.

Design and construction of a new human naïve single-chain fragment variable antibody library, IORISS1.

Pasello M, Zamboni S, Mallano A, Flego M, Picci P, Cianfriglia M, Scotlandi K.

J Biotechnol. 2016 Apr 20;224:1-11. doi: 10.1016/j.jbiotec.2016.02.034. Epub 2016 Mar 2.

PMID:
26945728
11.

Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.

Moricoli D, Carbonella DC, Dominici S, Fiori V, Balducci MC, Guerzoni C, Manara MC, Pasello M, Laguardia ME, Cianfriglia M, Scotlandi K, Magnani M.

Appl Microbiol Biotechnol. 2016 May;100(9):3949-63. doi: 10.1007/s00253-015-7226-5. Epub 2015 Dec 21.

PMID:
26685854
12.

CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.

Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K.

Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11.

13.

Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.

Sau A, Filomeni G, Pezzola S, D'Aguanno S, Tregno FP, Urbani A, Serra M, Pasello M, Picci P, Federici G, Caccuri AM.

Mol Biosyst. 2012 Apr;8(4):994-1006. doi: 10.1039/c1mb05295k. Epub 2011 Nov 9.

PMID:
22068640
14.

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.

Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M.

Anal Cell Pathol (Amst). 2011;34(3):131-45. doi: 10.3233/ACP-2011-012.

15.

Emerging drugs for high-grade osteosarcoma.

Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M.

Expert Opin Emerg Drugs. 2010 Dec;15(4):615-34. doi: 10.1517/14728214.2010.505603. Epub 2010 Aug 9. Review.

PMID:
20690888
16.

Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.

Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.

Clin Cancer Res. 2009 May 15;15(10):3550-6. doi: 10.1158/1078-0432.CCR-08-2249.

17.

Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines.

Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M.

Genes Chromosomes Cancer. 2009 Apr;48(4):289-309. doi: 10.1002/gcc.20640.

PMID:
19105235
18.

Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.

Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M.

Cancer Res. 2008 Aug 15;68(16):6661-8. doi: 10.1158/0008-5472.CAN-07-5840.

19.

Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.

Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M.

Ann Oncol. 2008 Aug;19(8):1500-8. doi: 10.1093/annonc/mdn148. Epub 2008 Apr 2.

PMID:
18385200
20.

May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S.

Int J Oncol. 2006 Dec;29(6):1459-68.

PMID:
17088985
21.

4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.

Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M.

Eur J Cancer. 2005 Sep;41(14):2184-95.

PMID:
16140527
22.

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.

Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P, Serra M.

Eur J Cancer. 2005 Jun;41(9):1349-61.

PMID:
15913990
23.

Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone.

Hattinger CM, Tarkkanen M, Benini S, Pasello M, Stoico G, Bacchini P, Knuutila S, Scotlandi K, Picci P, Serra M.

Eur J Cell Biol. 2004 Sep;83(9):483-91.

PMID:
15540465
24.

Effects of physical stimulation with electromagnetic field and insulin growth factor-I treatment on proteoglycan synthesis of bovine articular cartilage.

De Mattei M, Pellati A, Pasello M, Ongaro A, Setti S, Massari L, Gemmati D, Caruso A.

Osteoarthritis Cartilage. 2004 Oct;12(10):793-800.

25.

Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults.

Gemmati D, Ongaro A, Scapoli GL, Della Porta M, Tognazzo S, Serino ML, Di Bona E, Rodeghiero F, Gilli G, Reverberi R, Caruso A, Pasello M, Pellati A, De Mattei M.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94.

26.

Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.

Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P.

Ann Oncol. 2004 Jan;15(1):151-60.

PMID:
14679136
27.

Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.

Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, Manara MC, Scotlandi K, Picci P, Serra M.

Eur J Cell Biol. 2003 Sep;82(9):483-93.

PMID:
14582536
28.

Effects of electromagnetic fields on proteoglycan metabolism of bovine articular cartilage explants.

De Mattei M, Pasello M, Pellati A, Stabellini G, Massari L, Gemmati D, Caruso A.

Connect Tissue Res. 2003;44(3-4):154-9.

PMID:
14504035
29.

Effects of interleukin-1beta on chondroblast viability and extracellular matrix changes in bovine articular cartilage explants.

Stabellini G, De Mattei M, Calastrini C, Gagliano N, Moscheni C, Pasello M, Pellati A, Bellucci C, Gioia M.

Biomed Pharmacother. 2003 Sep;57(7):314-9.

PMID:
14499180
30.

High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro.

de Mattei M, Pellati A, Pasello M, de Terlizzi F, Massari L, Gemmati D, Caruso A.

Osteoarthritis Cartilage. 2002 Oct;10(10):816-25.

Supplemental Content

Loading ...
Support Center